September 18, 2019
Digital diabetes and chronic care company OneDrop has landed $40 million in a Series B funding round led by pharma giant Bayer. This news coincides with the announcement that Bayer inked a deal with the startup, entering into a commercial licensing agreement to use OneDrop’s platform.
This isn’t Bayer’s first foray into digital health. The company has its own accelerator in Germany that was...
May 7, 2019
Life sciences giant Bayer has joined forces with clinical AI technology company Sensyne Health to help develop a national linked patient data capability.
The German firm has signed a memorandum of understanding to be the preferred pharmaceutical partner in a consortium, which includes Microsoft, EY, JP Morgan, and Peel Hunt.
The consortium aims to accelerate the discovery and development of new...
January 23, 2019
Genomic and health data platform LunaDNA’s parent company, LunaPBC, has entered a partnership with Genetic Alliance, a nonprofit focused on delivering research and care opportunities to individuals and communities. Over the next year, LunaDNA will be merging its services with the Genetic Alliance’s engagement platform, strengthening both organizations’ efforts to solicit genetic research data...
April 12, 2018
ActiGraph activity monitors and a mobile app from Clinical Ink are are at the heart of a newly announced pilot study backed by Bayer, according to a statement released today by ActiGraph. The ongoing study is evaluating how these digital products and a Bluetooth-enabled weight scale are perceived by patients, and the feasibility of implementing such devices in future clinical trials run by the...
March 14, 2018
At HIMSS last week, Samsung announced a partnership with Travelers Insurance, Cedars-Sinai Medical Center, Bayer, and AppliedVR around using virtual reality for pain management. Samsung and Travelers will fund a 16-month study of between 90 and 140 patients, conducted at Cedars using technology from Samsung, Bayer, and AppliedVR.
"We just completed a randomized control trial that shows you can...
October 4, 2017
After running its G4A (Grants4Apps) program in Berlin for five years, Bayer is launching a new accelerator program in the United States, the company announced at Health 2.0’s Fall Conference in Santa Clara, California yesterday.
While the plans for the new venture, dubbed G4A Generator, are still being developed, Barton Warner, VP of strategy and portfolio management at Bayer, did share some...
June 16, 2017
Bayer recently received FDA approval for a connected auto-injector for relapsing-remitting multiple sclerosis medication and companion app. The device is called the Betaconnect Electronic Autoinjector and the app, due out in July, is myBetaApp.
The Whippany, New Jersey-based pharma company didn't clear the app and device through the 510(k) medical device pathway; instead the agency approved a...
September 27, 2016
The future of pharma is going to involve some major culture shifts for a business that has long been focused on slow development cycles, proprietary molecules, and close-held secrets. That’s the word from representatives from Bayer, Boehringer Ingelheim, Healthware International and BTG, a group that ran the gamut from small to big pharma at yesterday’s Pharma Roundtable onsite at Health 2.0 in...
May 14, 2015
Correction: This article previously mentioned strategic investors in MedoPad. The reference has been removed, as the companies in question were not actually investors.
A London hospital is the latest to put the Apple Watch to use within its walls, this time to improve medication management and adherence for cancer patients undergoing chemotherapy. According to a report from Wareable, King's...
January 13, 2015
Norwalk, Connecticut-based medication adherence platform company HealthPrize says it has succeeded in raising medication adherence an average of 54 percent across a series of pharma-sponsored pilot programs for various medical conditions, with sample sizes ranging from 250 to more than 7,000. That's a 54 percent increase in the mean total number of prescription fills per patient.